Premium Phosphosite-Specific 7TM Antibodies
Novel Tools for Your GPCR Research
Select Your Country of Delivery below

GPR65 Receptor Antibodies

Close filters
No results were found for the filter!
NEW
Validation of the GPR65 Receptor in transfected HEK293 cells.
GPR65 (non-phospho), G protein-coupled...
The non-phospho-GPR65 receptor antibody is directed against the distal end of the carboxyl-terminal tail of human GPR65. It can be used to detect total GPR65 receptors in Western blots independent of phosphorylation. The GPR65 antibody...
$ 400.00 *
Details

GPR65 is an orphan class-A G protein-coupled receptor. The endogenous ligand of GPR65 is still unknown. However, GPR4, GPR65, GPR68 and GPR132 are now thought to function as proton-sensing receptors detecting acidic pH. GPR65 is primarily expressed in immune cells, including T lymphocytes, macrophages, and monocytes, as well as in spleen and thymus tissues. It is also found in intestinal epithelial cells, suggesting a role in gut immune responses and inflammation. GPR65 has been shown to play a role in T cell activation and cytokine release, particularly in the context of immune cell signaling. GPR65 is considered a potential pharmacological target for autoimmune diseases and inflammatory disorders. Due to its involvement in regulating immune cell activation and cytokine production, modulating GPR65 activity could help treat conditions such as inflammatory bowel disease (IBD), rheumatoid arthritis, and other autoimmune diseases. For more information on GPR65 pharmacology please refer to the IUPHAR database. For further reading refer to:

Davenport AP, Alexander SP, Sharman JL, Pawson AJ, Benson HE, Monaghan AE, Liew WC, Mpamhanga CP, Bonner TI, Neubig RR, Pin JP, Spedding M, Harmar AJ. International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev. 2013 May 17;65(3):967-86. doi: 10.1124/pr.112.007179. PMID: 23686350; PMCID: PMC3698937.

Alexander SP, Battey J, Benson HE, Benya RV, Bonner TI, Davenport AP, Dhanachandra Singh K, Eguchi S, Harmar A, Holliday N, Jensen RT, Karnik S, Kostenis E, Liew WC, Monaghan AE, Mpamhanga C, Neubig R, Pawson AJ, Pin JP, Sharman JL, Spedding M, Spindel E, Stoddart L, Storjohann L, Thomas WG, Tirupula K, Vanderheyden P. Class A Orphans in GtoPdb v.2023.1. IUPHAR/BPS Guide to Pharmacology CITE. 2023; 2023(1). Available from: https://doi.org/10.2218/gtopdb/F16/2023.1.

GPR65 is an orphan class-A G protein-coupled receptor. The endogenous ligand of GPR65 is still unknown. However, GPR4, GPR65, GPR68 and GPR132 are now thought to function as proton-sensing... read more »
Close window
GPR65 Receptor Antibodies

GPR65 is an orphan class-A G protein-coupled receptor. The endogenous ligand of GPR65 is still unknown. However, GPR4, GPR65, GPR68 and GPR132 are now thought to function as proton-sensing receptors detecting acidic pH. GPR65 is primarily expressed in immune cells, including T lymphocytes, macrophages, and monocytes, as well as in spleen and thymus tissues. It is also found in intestinal epithelial cells, suggesting a role in gut immune responses and inflammation. GPR65 has been shown to play a role in T cell activation and cytokine release, particularly in the context of immune cell signaling. GPR65 is considered a potential pharmacological target for autoimmune diseases and inflammatory disorders. Due to its involvement in regulating immune cell activation and cytokine production, modulating GPR65 activity could help treat conditions such as inflammatory bowel disease (IBD), rheumatoid arthritis, and other autoimmune diseases. For more information on GPR65 pharmacology please refer to the IUPHAR database. For further reading refer to:

Davenport AP, Alexander SP, Sharman JL, Pawson AJ, Benson HE, Monaghan AE, Liew WC, Mpamhanga CP, Bonner TI, Neubig RR, Pin JP, Spedding M, Harmar AJ. International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev. 2013 May 17;65(3):967-86. doi: 10.1124/pr.112.007179. PMID: 23686350; PMCID: PMC3698937.

Alexander SP, Battey J, Benson HE, Benya RV, Bonner TI, Davenport AP, Dhanachandra Singh K, Eguchi S, Harmar A, Holliday N, Jensen RT, Karnik S, Kostenis E, Liew WC, Monaghan AE, Mpamhanga C, Neubig R, Pawson AJ, Pin JP, Sharman JL, Spedding M, Spindel E, Stoddart L, Storjohann L, Thomas WG, Tirupula K, Vanderheyden P. Class A Orphans in GtoPdb v.2023.1. IUPHAR/BPS Guide to Pharmacology CITE. 2023; 2023(1). Available from: https://doi.org/10.2218/gtopdb/F16/2023.1.

Recently viewed